Overview

PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES

Status:
Completed

Trial end date:
2017-03-30

Target enrollment:

Participant gender:

Summary

Capecitabine, oxaliplatin, irinotecan and bevacizumab as perioperative strategy of borderline and/or high risk resectable colorectal cancer liver metastases

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Treatments:

Bevacizumab
Camptothecin
Capecitabine
Irinotecan
Oxaliplatin